Targeted radiation therapy for advanced prostate cancer
Part of Cancer clinical trials.
This trial tests a new type of targeted radiation therapy (called 161Tb-NYM032) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the treatment is safe, tolerable, and helps slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older with metastatic castration-resistant prostate cancer, meaning the cancer has spread and is no longer responding to hormone therapy.
- You have had a special PET/CT scan (called 68Ga-NYM032) that shows the cancer clearly, which is necessary to join.
- You have already tried at least one next-generation hormone drug (like enzalutamide or abiraterone) or one taxane chemotherapy, or you cannot tolerate or decline chemotherapy.
- You are generally in good health – able to do daily activities and walk (ECOG 0–2) – and your doctor expects you to live at least 6 more months.
- Your blood counts and liver/kidney function tests meet minimum levels (such as white blood cells, platelets, and hemoglobin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
This trial tests a new treatment that targets a protein called PSMA found on prostate cancer cells. It uses a radioactive form of the treatment to try to kill cancer cells while limiting damage to healthy cells. This study is for men with advanced prostate cancer that has stopped responding to other treatments.
This study tests a new experimental treatment for advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The treatment is a radioactive drug that targets a protein called PSMA on cancer cells, aiming to deliver radiation directly to the tumor.
This trial tests a new radioactive treatment, called 177Lu-NYM032, for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It aims to see if this treatment can slow the cancer's growth and improve outcomes.
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.